EGFR and metastatic colorectal cancer: Recently, in the phase III trial CodeBreaK 300 investigating KRAS G12C inhibitor plus an EGFR inhibitor in patients with chemorefractory metastatic colorectal cancer, both doses of sotorasib in combination with panitumumab resulted in longer progression-free survival than standard treatment [164].